Procyon Corporation (PCYN) Stock Analysis & Winston Score
Procyon Corporation is a small healthcare company that makes and sells specialty pharmaceutical and personal care products. Its lineup includes topical treatments and wellness products sold mainly to consumers and healthcare providers in the United States. The company operates in the specialty and generic drug space, where it competes against much larger manufacturers. Procyon earns revenue by selling its products directly and through distributors, relying on product sales rather than subscriptions or licensing. It is a very small company, with a market cap that rounds to essentially zero, and it lacks the scale or patent portfolio that larger drug makers use to defend their market position. The company is currently unprofitable, with negative operating and return-on-capital margins, meaning its main challenge is cutting costs and growing sales fast enough to reach breakeven before it runs low on resources.
Winston Score: 31/100 — Below Average
Below-average fundamentals — multiple weak pillars.
- Quality: Weak (7/30)
- Growth: Mixed (5/20)
- Cash Flow: Weak (1/10)
- Stability: Good (5/10)
- Valuation: Weak (1/10)
- Ownership: Good (10/15)
Key Facts
Price: $0.17
Market Cap: $1M
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

